Menus Subscribe Search

Follow us


Defeating Bacteria From the Inside Out

• April 19, 2012 • 4:03 PM

The world’s most ubiquitous organism could save millions of lives — if only they could get a new tryout.

Bacteriophages, a class of viruses that only attack bacteria, have been controversial ever since their discovery by a brash, young, self-taught researcher named Felix d’Herelle nearly a century ago.

In the 1920s and ’30s, before the advent of antibiotics, doctors using phage therapy reported near miraculous cures for infections, even at the critical stage. The treatments, however, didn’t work in every case, and after the discovery of much more reliable antibiotics, starting with penicillin in the 1940s, phage therapy was ushered off the medical stage in the United States and Western Europe.

Anna Kuchment, an editor at Scientific American, labeled phage therapy The Forgotten Cure in her recent book, in which she says the practice took up residence behind the Iron Curtain where antibiotics were scarce.

Alexander Sulakvelidze, who grew up in Tbilisi, Georgia, says phage therapy was there for him when he was a child. “Everybody took them when they got sick. It was just something you did.”

Although we now take penicillin and its host of antibiotic descendants for granted, scientists say with the emergence of more strains of antibiotic-resistant disease, it may be just a matter of time before we are forced to seek some alternatives, and researchers suggest that phage therapy may be just the ticket. And since the end of the Cold War, word has been trickling out that phage therapy still works.

• • • • • • • • • • • • • • •

Forty times smaller than the bacteria they prey upon, each species of phage hones in on one specific type of bacteria. Finding its target, a phage attaches to its bacterial host and deliver a dose of DNA that converts the bacteria into a factory to make more phages — eating the germ from the inside out.

Phages can be found almost anywhere there is water (including the human nostril); they may be the most common organism on Earth. Mankind is awash in them, says Sulakvelidze, who grew up to be chief science officer for Intralytix, a Baltimore-based manufacturer of phage-based products.

For an effective therapy, proponents note, caregivers need to identify a pathogen precisely, then pick the exact species of phage that attacks it. (Antibiotics can work without knowing the specific bacterium because they attack a broad spectrum of bacteria.) The ability to identify the offending bacteria, although not foolproof, is much improved by genetic analysis and other means not available during 1930s.

Still, well-understood bacterial diseases like shigella, a disease of the digestive tract, make a good starting point for deploying phages. If phage therapy were more widely available, Sulakvelidze said, “and you saved just 10 percent of the 700,000 children killed each year by shigella, it would be mind boggling.”

And while they’re fast acting, beginning the process of breaking down targeted bacteria within minutes of application, when phages are done destroying bacteria they become inactive, he adds.

“There would be no downside to trying [phage therapy],” he argues, “The worst-case scenario would be that it did not work — it’s pretty well established that it could do no harm.”

(Because bacteria can be cagey opponents, Sulakvelidze says it would be best to use a variety of species of phage in a cocktail, to be sure to eliminate both the target strain and any closely related variants that might arise during an infection.)

Too good to be true? In a way.

Phage therapy is not a panacea, Sulakvelidze says. “Baseless claims” made by early enthusiasts helped to diminish phage therapy’s reputation in the past.

For instance, he contrasts shigella with tuberculosis, for which it’s “difficult to imagine” a phage-based treatment. That’s in part because the phage cannot get inside of human cells where TB takes up residence, nor can they easily pursue the TB bacterium to the various parts of the body where it hides out.

• • • • • • • • • • • • • • •

The road to market is not an easy one, and experts say for a new antibiotic getting through the administrative hurdles can take years and cost in the neighborhood of $100 million, with the essential requirement of the double-blind clinical trial.

Dr. Glenn Morris, director of the Emerging Pathogens Institute at the University of Florida, co-founded Intralytix, Inc., with Sulakvelidze. While subsequent applications have gone more smoothly, he said, the U.S. Food and Drug Administration approval process for ListShield, the firm’s first phage-based product targeting listeria in food, took four years to reach the approval stage. Morris says that was “largely because there was no standard channel at the FDA for considering phage-based products.”

Phage preparations, by their nature need to be individualized in order to perform at their best. Ideally, Sulakvelidze says, an appropriate regulatory process would take a non-traditional approach, granting manufacturers the flexibility to mix and match phage combinations to address distinct outbreaks, or individual cases, without having to re-enact the entire clinical trial procedure every time they target a phage against a different bacterium.

Bill Egan, the former acting director of the FDA Office of Vaccine Research and Review, says he can see some logic in that approach. He envisions a process similar to the one used for approving annual influenza vaccines, which allows manufacturers to obtain approval based for new versions of influenza vaccines without the necessity for repeated large-scale clinical trials.

He says after first demonstrating that phage therapy can be performed with safety and efficacy, manufacturers of phage treatments would then need to be able to show they “have a procedure in place to handle the individual outbreak, that they have a way to determine the efficacy of therapy.” And finally they would need to demonstrate that when they put a phage preparation together “that it is effective.”

Although the FDA approval process can be arduous, Egan says, it’s flexible. The agency, “as much as anybody else, wants to see safe and effective products go out on the market.”

Ultimately, Egan says the test of phage therapy will be public acceptance. “The physicians will have their set criteria and patients will have theirs. That happens with any new thing, this happened when generics were first introduced; there was a lot of resistance. Now everybody takes them.”

David Richardson
David Richardson began his journalism career operating a video news service in Washington, D.C., that covered federal agencies and Congress. His film production work has since ranged from postings at the White House to rural villages of Botswana, documenting community-centered HIV prevention programs. He holds a B.A. degree in government from Dartmouth College. He now writes on science, the environment and policy from Baltimore, Md., where he's had some success growing organic produce in a small backyard garden.

More From David Richardson

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

December 17 • 4:00 PM

How to Run a Drug Dealing Network in Prison

People tend not to hear about the prison drug dealing operations that succeed. Substance.com asks a veteran of the game to explain his system.


December 17 • 2:00 PM

Gender Segregation of Toys Is on the Rise

Charting the use of “toys for boys” and “toys for girls” in American English.


December 17 • 12:41 PM

Why the College Football Playoff Is Terrible But Better Than Before

The sample size is still embarrassingly small, but at least there’s less room for the availability cascade.


December 17 • 11:06 AM

Canadian Kids Have a Serious Smoking Problem

Bootleg cigarette sales could be leading Canadian teens to more serious drugs, a recent study finds.


December 17 • 10:37 AM

A Public Lynching in Sproul Plaza

When photographs of lynching victims showed up on a hallowed site of democracy in action, a provocation was issued—but to whom, by whom, and why?


December 17 • 8:00 AM

What Was the Job?

This was the year the job broke, the year we accepted a re-interpretation of its fundamental bargain and bought in to the push to get us to all work for ourselves rather than each other.


December 17 • 6:00 AM

White Kids Will Be Kids

Even the “good” kids—bound for college, upwardly mobile—sometimes break the law. The difference? They don’t have much to fear. A professor of race and social movements reflects on her teenage years and faces some uncomfortable realities.



December 16 • 4:00 PM

How Fear of Occupy Wall Street Undermined the Red Cross’ Sandy Relief Effort

Red Cross responders say there was a ban on working with the widely praised Occupy Sandy relief group because it was seen as politically unpalatable.


December 16 • 3:30 PM

Murder! Mayhem! And That’s Just the Cartoons!

New research suggests deaths are common features of animated features aimed at children.


December 16 • 1:43 PM

In Tragedy, Empathy Still Dependent on Proximity

In spite of an increasingly connected world, in the face of adversity, a personal touch is most effective.


December 16 • 12:00 PM

The ‘New York Times’ Is Hooked on Drug du Jour Journalism

For the paper of record, addiction is always about this drug or that drug rather than the real causes.


December 16 • 10:00 AM

What Is the Point of Academic Books?

Ultimately, they’re meant to disseminate knowledge. But their narrow appeal makes them expensive to produce and harder to sell.


December 16 • 8:00 AM

Unjust and Unwell: The Racial Issues That Could Be Affecting Your Health Care

Physicians and medical students have the same problems with implicit bias as the rest of us.


December 16 • 6:00 AM

If You Get Confused Just Listen to the Music Play

Healing the brain with the Grateful Dead.


December 16 • 4:00 AM

Another Casualty of the Great Recession: Trust

Research from Britain finds people who were laid off from their jobs expressed lower levels of generalized trust.


December 15 • 4:00 PM

When Charter Schools Are Non-Profit in Name Only

Some charters pass along nearly all their money to for-profit companies hired to manage the schools. It’s an arrangement that’s raising eyebrows.


December 15 • 2:00 PM

No More Space Race

A far cry from the fierce Cold War Space Race between the U.S. and the Soviet Union, exploration in the 21st century is likely to be a much more globally collaborative project.


December 15 • 12:32 PM

The Hidden Psychology of the Home Ref

That old myth of home field bias isn’t a myth at all; it’s a statistical fact.


December 15 • 12:00 PM

Gluttony and Global Warming: We’re Eating Ourselves to a Warmer Planet

Forget your car. Our obsession with beef and dairy has a far more devastating effect on the climate.


December 15 • 10:00 AM

The 2016 Presidential Race Has Already Started

And this is the most exciting part.


December 15 • 8:00 AM

The Second Life of Old iPods

Why is it that old iPods are suddenly cool—and pricey again?


December 15 • 6:00 AM

The Lifelong Consequences of Rape

The long-term psychological and physical effects of the experience are devastating. And they’re likely exacerbated by the shame our culture insists on perpetuating.


December 15 • 4:00 AM

Mating Mindset Interferes With Attempts to Stop Smoking

Taiwanese researchers find photos of attractive women put men in an immediate-gratification state of mind.


December 15 • 2:00 AM

Where Innovation Thrives

Innovation does not require an urban area or a suburban area—it can happen in the city or in a small town. What it requires is open knowledge networks and the movement of people from different places.


Follow us


Canadian Kids Have a Serious Smoking Problem

Bootleg cigarette sales could be leading Canadian teens to more serious drugs, a recent study finds.

The Hidden Psychology of the Home Ref

That old myth of home field bias isn’t a myth at all; it’s a statistical fact.

A Word of Caution to the Holiday Deal-Makers

Repeat customers—with higher return rates and real bargain-hunting prowess—can have negative effects on a company’s net earnings.

Crowdfunding Works for Science

Scientists just need to put forth some effort.

There’s More Than One Way to Be Good at Math

Mathematical ability isn’t one single skill set; there are indeed many ways to be “good at math,” research shows.

The Big One

One in two United States senators and two in five House members who left office between 1998 and 2004 became lobbyists. November/December 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.